We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Aptorum Group Ltd (APM) USD1 A

Sell:$1.84 Buy:$1.95 Change: $0.04 (2.14%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
Change: $0.04 (2.14%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
Change: $0.04 (2.14%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Aptorum Group Limited is a biopharmaceutical company dedicated to developing and commercializing therapeutics for unmet medical needs. It is pursuing therapeutic projects in neurology, infectious diseases, gastroenterology, oncology and other. Its projects include Smart-Act series, Acticule series, RPIDD, Nativus series and Claves series. SMART-ACT is a drug delivery platform, focused on orphan diseases. SMART-ACT pipeline includes SACT-1 and SACT-COV19. Its Acticule series includes ALS-4, ALS-1 and ALS-2/3. ALS-4 is an anti-virulent, non-bacterial drug candidate for staphylococcus aureus infections. ALS-1 is an antiviral therapeutic against Influenza A. ALS-3/3 is an anti-virulent, non-bacterial approach therapeutics targeting Gram-positive bacteria. RPIDD is therapeutic against infection disease. Nativus series includes NativusWell (NLS-2), nutraceutical supplement targeting women who are between 45 ad 65 years old and experiencing menopausal, premenopausal, postmenopausal syndrome.

Contact details

17 Hanover Square
United Kingdom
+44 (20) 80929299

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$66.62 million
Shares in issue:
35.61 million
Cayman Islands
US dollar

Key personnel

  • Darren Lui
    President, Executive Director
  • Ian Huen
    Chief Executive Officer, Founder, Executive Director
  • Sabrina Khan
    Chief Financial Officer
  • Angel Ng
    Chief Operating Officer
  • Clark Cheng
    Chief Medical Officer and Executive Director
  • Thomas Lee
    Head of Research and Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.